You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家藥監局就藥品網絡銷售禁止清單公開徵求意見
國家藥監局公布,就起草《藥品網絡銷售禁止清單(徵求意見稿)》公開徵求意見,明確禁止銷售的藥品包括疫苗、血液製品、麻醉藥品、精神藥品、醫療用毒性藥品、放射性藥品、藥品類易製毒化學品、醫療機構製劑及中藥配方顆粒。
其他禁止通過網絡零售的藥品包括注射劑(降糖類藥物除外)、含麻黃堿類複方製劑、《興奮劑目錄》所列的蛋白同化製劑和(月太)類激素((胰島素除外),以及用藥風險較高的品種如地高辛及丙(口比)胺等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.